NCT06171178View on ClinicalTrials.gov

A Study of ASP1012 in Adults With Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Solid Tumor
Interventions
DRUG

ASP1012

Intravenous (IV) infusion

DRUG

Pembrolizumab

IV infusion

Trial Locations (8)

14263

Roswell Park Cancer Institute, Buffalo

30322

Emory Winship Cancer Institute, Atlanta

44718

Gabrail Cancer and Research Center, Canton

48201

Karmanos Cancer Institute, Detroit

52242

University of Iowa Hospitals, Iowa City

75230

Mary Crowley Cancer Research, Dallas

90025

The Angeles Clinic and Research Institute, Los Angeles

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT06171178 - A Study of ASP1012 in Adults With Solid Tumors | Biotech Hunter | Biotech Hunter